The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Breast CancerDepression
Interventions
DRUG

Melatonin (N-acetyl-5-methoxytryptamine)

6 mg oral melatonin daily 1 hour before bedtime

DRUG

Placebo

6 mg oral placebo daily 1 hour before bedtime

Trial Locations (1)

2730

Herlev Hospital, Copenhagen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Copenhagen

OTHER

collaborator

Rigshospitalet, Denmark

OTHER

collaborator

Pharma Nord

INDUSTRY

lead

Melissa Voigt Hansen

OTHER

NCT01355523 - The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients | Biotech Hunter | Biotech Hunter